SMSbiotech is pleased to announce the appointment of Joe Kiani, a renowned healthcare leader and innovator, as Chairman of the Board of Directors. His appointment marks an important milestone for the company as it continues advancing its clinical-stage regenerative medicine platform and expanding the development of novel cell-based therapies.
Kiani brings decades of leadership experience in healthcare innovation and mission-driven organizations. He is widely recognized as the founder of Masimo, a global medical technology company dedicated to improving patient outcomes through advanced monitoring technologies. He is also the founder of Willow Laboratories, an organization focused on developing innovative health technology solutions designed to transform healthcare delivery.
With extensive strategic insight and operational expertise, Kiani will support SMSbiotech as the company accelerates clinical development and continues expanding its regenerative medicine platform.
“Mr. Kiani, an early supporter of SMSbiotech, will bring invaluable expertise and strategic insight to help propel the company to the forefront of regenerative cell therapy,” said Dr. Abdulkader Rahmo, President of SMSbiotech. “We are deeply honored to welcome Joe as Chair of the Board at this pivotal moment. His commitment reflects strong confidence in our science, our platform, and our long-term vision to transform how degenerative diseases are treated.”
In his role as Chairman, Kiani will work closely with SMSbiotech’s Board of Directors and executive leadership to help refine corporate strategy, support the advancement of clinical programs, and guide the company toward long-term growth and commercialization. His leadership is expected to play a pivotal role in strengthening SMSbiotech’s strategic direction and accelerating its mission to develop safe and effective regenerative therapies for patients with chronic and degenerative conditions.
“I am honored to join SMSbiotech as Chairman at a time when the company’s science is translating into real potential for patients,” said Joe Kiani. “I look forward to supporting the team as they advance innovative regenerative therapies and work toward improving patient care globally.”
This appointment reinforces SMSbiotech’s commitment to leadership excellence, scientific innovation, and strategic growth as the company continues building momentum in clinical development and expanding its pipeline of regenerative therapies.
As SMSbiotech moves forward, the company remains focused on advancing breakthrough regenerative solutions that aim to improve outcomes for patients living with chronic and degenerative diseases.
